Endothelial cell (EC) injury and the response of EC and smooth muscle cells (SMCs) to injury contribute to the pathophysiology in patients with vascular disease and atherosclerosis. Since platelets have been suggested to play an important role in modulating vascular injury, the present study was undertaken to examine the influence and mechanism of action of individual platelet factors on bovine aortic EC and SMC migration using an in vitro wound assay system. Serotonin decreased EC proliferation and reduced EC migration 21±1% (p<0.005), which was attenuated by imipramine. Transforming growth factor-^ reduced EC proliferation and decreased EC migration 52±3% (/><0.005). Norepinephrine increased EC proliferation but decreased EC migration 26±2% (p< 0.005), which was abolished by phenoxybenzamine. Histamine increased EC proliferation but reduced EC migration 29±2% ( / K O . 0 0 5 ) , which was attenuated by diphenhydramine. Platelet-derived growth factor decreased EC proliferation and decreased EC migration 40±2% (p<0.005). In contrast, serotonin increased SMC proliferation and increased SMC migration 31±2% (p<0.005), which was abolished by ketanserin. Transforming growth factor-/? increased SMC migration 35±5% (p<0.005). Norepinephrine increased SMC proliferation and increased SMC migration 43 ± 4 % (/?< 0.005), which was abolished by propranolol. Histamine increased SMC proliferation and increased SMC migration 38±3% (/><0.005), which was abolished by cimetidine. Platelet-derived growth factor increased SMC proliferation and increased SMC migration 40±3% (p<0.005). Changes in migration were unaffected by growth-arresting treatment. Hence, these individual platelet factors inhibit EC migration and augment SMC migration via specific receptors and independent of proliferation changes. These results suggest mechanisms in which platelet factors may contribute to blood vessel injury in vivo. (Circulation Research 1989;65:1057-1065) E ndothelial cell injury and the subsequent response to this injury by both endothelial cells and vascular smooth muscle cells are thought to be important contributors to the pathophysiology of hypertension, ischemia, hyperlipidemia, focal vasospasm, and diabetic vascular disease and of the vascular impairment following reperfusion, coronary angioplasty, and coronary
artery bypass graft placement. 1 -6 Accumulation of platelets at the sites of endothelial cell injury and the release of soluble factors from these cells have been proposed to be important mediators of the blood vessel wall response to injury.
2 Therapy directed at reducing platelet effects on the blood vessel wall is a mainstay in the treatment of ischemic disease.
1 -3 - 6 Previous investigations have demonstrated that the response of the blood vessel wall to a denuding injury of the endothelium involves 1) proliferation and migration of the remaining endothelial cells to close the wound and 2) secondary proliferation and migration of the medial smooth muscle cells into the intima resulting in intimal hyperplasia. 2 However, the influence of individual platelet factors on vascular cell migration has not been defined.
The present study was undertaken to identify the influence of specific platelet factors-serotonin, transforming growth factor-/3 (TGF-/J), histamine, norepinephrine, and platelet-derived growth factor -on the kinetics of endothelial and smooth muscle cell migration. An in vitro wound assay was used in which radial migration is quantified after release of endothelial and smooth muscle cell monolayers from contact inhibition. The contribution of factor-mediated changes in proliferation to the observed changes in migration with each of the agents was also identified. Further, the role of stimulation of specific membrane receptors in mediating the alterations in migration kinetics was assessed.
Materials and Methods

Endothelial Cell Culture
Bovine calf aortic endothelial cells were isolated and cultured as previously described. 10 Endothelial cells were grown in Dulbecco's modified Eagle Medium (GIBCO, Grand Island, New York) with 10% fetal calf serum and penicillin and streptomycin. Cells were passaged with trypsin/EDTA and used for passages three through 12. The endothelial cell nature of the cultures was confirmed by immunofluorescence staining for the presence of factor Vlll-related antigen (rabbit antibody to human factor Vlll-associated protein, CalbiochemBehring, LaJolla, California) and di-acetylated low density lipoprotein uptake (Miles Laboratories, Elkhart, Indiana).
Vascular Smooth Muscle Cell Culture
Bovine calf aortic smooth muscle cells were isolated and cultured as previously described. 11 Smooth muscle cells were used only for passages two through six. The smooth muscle cell nature of the cells was consistent with the positive immunofluorescence staining for desmin and the lack of staining for factor VTII-related antigen.
Mitomycin Assay
In preliminary studies, the influence of mitomycin C (Sigma Chemical, St. Louis, Missouri) on endothelial and smooth muscle cell proliferation was assessed in subconfluent cultures of cells in 35-mm Bacteriologic Plastic Petri dishes coated with 12.5 Aig/ml type I collagen in 50 mM carbonate buffer (pH 9.3). 12 In separate experiments, 20,000 cells were plated onto dishes, allowed to attach in media, removed with trypsin/EDTA and the samples were counted in a Coulter counter (Coulter Electronics, Hialeah, Florida) to assess baseline cell number before treatment. Cultures were then treated for 2 hours at 37° C with mitomycin C at a final concentration of 0, 1, 5, 10, or 20 //.g/ml. The cultures were washed with phosphate-buffered saline and then incubated for 4 days in media without mitomycin. For the smooth muscle cell doseresponse assays, samples were counted in a Coulter counter at the end of the incubation period. At the end of the incubation period, smooth muscle cells treated with 10 ^g/ml mitomycin maintained a stable cell number, showing no significant increase in number (increased 0±l% of the increase of untreated cells,/><0.005, n=5). For the endothelial cell assays, cultures were counted in a Coulter counter as above and the relative labeling index was also calculated in each dish with [ ]thymidine was added to each dish to reach a final concentration of 1 /iCi/ml. The samples were incubated for 3 hours at 37° C, washed with phosphate-buffered saline, and then incubated for 1 hour in media. After harvesting the counts with 10% trichloroacetic acid, the samples were counted for 10-minute acquisitions in Opti-fluor (Packard, Downers Grove, Illinois) in a scintillation counter (Beckman LS-230 liquid scintillation counter system, Beckman Instruments, Fullerton, California), and the relative labeling index was calculated as number of counts per dish. At the end of the incubation period, endothelial cells treated with 10 ^g/ml mitomycin maintained a stable cell number and showed no significant increase in number (increased 2±0%, p<0.005, «=3 of the increase of untreated control cultures), and the labeling index was reduced to l±0% (p<0.005 versus labeling index of untreated cells, n=3) of the labeling index of untreated control cultures. The presently employed dose of mitomycin and the duration of treatment of cells are similar to that employed by other investigators.
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Migration Assay
The migration kinetics of untreated and mitomycintreated endothelial and smooth muscle cell monolayers were examined using a Teflon fence assay as previously described. 15 Briefly, a confluent monolayer of cells was established in the well of the fence on a substrate of type I collagen. Endothelial and smooth muscle cell migration and proliferation resulted from release of contact inhibition by removal of the fence. After removal of the fence, treatment factors were added to the medium. On day 3, the cultures were washed, refed, and fresh aliquots of treatment factors were added. To determine the reversibility of the factor-mediated changes in migration, in certain subsets of experiments, the changes in migration were compared in cultures that received factor treatments only for days 1-3 or for days 4-6. On day 6, the cultures were washed with phosphatebuffered saline, fixed with mcthanol, and stained with Harris' hematoxylin. For each culture^ migration rate was calculated as the net increase in surface area measured using an overhead projector after digitization with a computerized graphics tablet. Migration of treated cultures was compared with untreated culture? and expressed as a percentage change in fate over the 6 days relative to untreated cultures. Cultures treated with both platelet factors and mitomycin were compared with cultures treated with mitomycin alone and expressed as a percentage change in rate over the 6 days. All comparisons of cultures were in experiments per-formed simultaneously with cells at the same passage and from the same isolate.
Proliferation Assay
Changes in the proliferation rate of migrating endothelial and smooth muscle cell cultures were determined. Endothelial cell labeling index was calculated as labeled nuclei in the field per total nuclei in the field and measured with [ 3 H]thymidine autoradiography where the radioisotope was administered on day 2 and individual labeled and unlabeled nuclei were counted after autoradiography with Ilford K.5d emulsion (Ilford Scientific Product, Mobberley, UK) and staining with Harris' hematoxylin. For each treatment, total and labeled nuclei were counted in a separate field on each of three dishes in the two leading zones of migration based on the morphological criteria originally described by Gotlieb et al 16 with zone 1 defined as the leading five rows of cells and zone 2 as the next five to 10 rows of elongated cells. Smooth muscle cell proliferation was determined by removing cells from migrating cultures with trypsin/EDTA and counting the number of cells in untreated and treated migration cultures with a Coulter counter at the end of the 6-day migration period.
Platelet Factors
In the endothelial cell experiments, histamine dihydrochloride (Sigma Chemical) and norepinephrine bitartrate (Breon Laboratories, New York, New York) were administered at a final concentration of 1 fiM, serotonin creatinine sulfate (Sigma Chemical) at a final concentration of 0.1 /xM, TGF-P (generous gift from Drs. Anita Roberts and Michael Sporn, Laboratory of Chemoprevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland) at a final concentration of 0.5 ng/ml, and hPDGF (Collaborative Research) at a final concentration of 2.5 IU/ml except in the doseresponse experiments where histamine, norepinephrine, and serotonin were at a final concentration of 10 /xM, TGF-/3 was at a final concentration of 0.05 ng/ml, and PDGF was at a final concentration of 1.0 IU/ml. In the smooth muscle experiments, histamine, norepinephrine, and serotonin were all administered at final concentrations of 1 /*M, TGF-0 was administered at a final concentration of 0.5 ng/ml, and PDGF was administered at a final concentration of 2.5 IU/ml. Each of the following antagonists were administered at a final concentration of 1 /iM: imipramine hydrochloride (Sigma Chemical), ketanserin tartrate (Janssen Pharmaceutica, Beerse, Belgium), methiothepin maleate (Hoffman-LaRoche, Nutley, New Jersey), diphenhydramine hydrochloride (Sigma Chemical), cimetidine (Sigma Chemical), propranolol hydrochloride (Ayerst Laboratories, New York, New York), and phenoxybenzamine hydrochloride (Smith Kline & French Laboratories, Philadelphia, Pennsylvania). In addition, the nonplatelet factors heparin (Sigma Chemical) and recombinant basic fibroblast growth factor (bFGF; generous gift from Drs. Judah Folkman and Michael Klagsbrun, Children's Hospital, Boston, Massachusetts) were administered at final concentrations of 100 IU/ml and 2.0 ng/ml, respectively. All chemicals were freshly prepared in sterile phosphate-buffered saline for each experiment.
Statistical Analysis
Changes in migration of both endothelial and smooth muscle cells with and without individual antagonists, proliferation of both cell types with mitomycin, and changes in proliferation of smooth muscle cells during migration were averaged for experiments performed under similar conditions, expressed as the mean±l SEM, and analyzed by one-way analysis of variance. If the global hypothesis tested by the initial analysis of variance that all means were equal was rejected, then individual comparisons were made between means of samples studied under similar conditions. A priori comparisons were performed using the least significant difference test and a posteriori comparisons were made using the least significant range test. 17 Corrections for multiple comparisons were made using the method of Bonferroni. For the analysis of changes in the proliferation of migrating endothelial cells, Fisher's exact test was employed. 17 For all comparisons, statistical significance was assumed as/?<0.05.
Results
Bovine Aortic Endothelial Cell Migration
Each of the five platelet factors was associated with a significant and reversible decrease in endothelial cell migration as illustrated in Table 1 . The changes in migration were independent of the associated changes in proliferation since they were unaffected by pretreatment with the growtharresting agent mitomycin. For the amines, the changes in migration were mediated by specific receptor mechanisms. In addition, incubation of migrating cultures with the individual antagonists alone was not associated with changes in migration (data not shown). For each of the factors there was a dose-dependent decrease in migration. The reduction in migration of 29±1% (/?<0.005, « = 18) with 10 (iM serotonin was significantly {p <0.01) greater than the 21±1% (p <0.005, n=18) inhibition associated with 0.1 fiM serotonin. TGF-/3 (0.5 ng/ml) decreased migration 55±1% (p<0.005, n=5), and TGF-/3 (0.05 ng/ml) decreased migration significantly less (decrease of 36±2% [p<0.005 versus control] and 0.5 ng/ml, n=5). The effect of norepinephrine was dose dependent since the 43 ±2% (/><0.005, n=5) decrease in migration with 10 /iM norepinephrine was significantly (p <0.05) greater than the 32 ±2% (p < 0.005, n =5) decrease in migration with 1 fiM norepinephrine. The 50±2% (/><0.005, n=5) decrease in migration with 10 fiM histamine was significantly (p <0.005) greater than ...
-30* -37* 5HT, serotonin; NE, norepinephrine; FIIS, histamine; TGF-/3, transforming growth factor-^; PDGF, plateletderived growth factor; MITO, mitomycin; IMIP, imipramine; KET, ketanserin; MET, methiothepin; PBZ, phenoxybenzamine; PROP, propranolol; DIP, diphenhydramine; CIM, cimctidinc. For each factor, the effect of treatment for days 1-3 and for days 4-6 did not differ from each other, and each was significantly less than the effect of treatment for days [1] [2] [3] [4] [5] [6] Endothelial cell migration did not change with 2 ng/ml bFGF (decrease of 3±3%, /> = NS, n=l). Mitomycin treatment was associated with a 7 ±2% (p<0.05, «=31) decrease in endothelial cell migration as compared with untreated endothelial cells.
Bovine Aortic Smooth Muscle Cell Migration
Each of the five platelet factors was associated with a significant increase in tiie migration rate of smooth muscle cells as illustrated in Table 2 . The changes in migration were independent of the associated changes in proliferation since they were unaffected by pretreatment with the growtharresting agent mitomycin. Further, the increases in migration associated with the three amines were due to activation of specific receptor systems. However, incubation of the cultures with the specific antagonists, alone, was not associated with changes in migration (data not shown).
Smooth muscle cell migration decreased 25±2% (/?<0.QQ5, n=l) with 100 IU/ml heparin treatment. Growth-arrested smooth muscle cells migrated 17±3% Cp<0.005, rc=10) less than non-growtharrested smooth muscle cells. Discussion The present data demonstrate that each of the five soluble platelet factors-serotonin, TGF-0, norepinephrine, histamine, and PDGF-decrease the migration rate of aortic endothelial cells and increase the migration rate of aortic smooth muscle cells in an in vitro wound assay. As illustrated in Figure 1 , this study also identifies the effect of each of these factors on the proliferation rate of migrating vascular cells and the subsequent influence of the factormediated changes in proliferation on migration kinetics. Furthermore, the role of activation of specific membrane receptors in mediating the changes in migration rate is also identified.
Endothelial cell migration is decreased by these individual platelet factors. Serotonin, TGF-0, and PDGF decrease both endothelial cell migration and proliferation. The effect of serotonin is largely mediated via active uptake of serotonin into endothelial cells. 18 -19 Norepinephrine and histamine both decrease endothelial cell migration despite increasing proliferation. The norepinephrine effect is accomplished through a-adrenergic receptor stimulation, and histamine decreases endothelial cell migration via H! receptor stimulation and, to a lesser extent, H 2 receptor stimulation. All of these factormediated changes in migration rate are independent of changes in proliferation since similar changes are observed in growth-arrested cells.
Smooth muscle cell migration is increased by these platelet factors. Each of the five factors except for TGF-0 also increase the proliferation rate of migrating smooth muscle cells. Serotonin mediates its effect through S 2 receptor stimulation, norepinephrine via /3-adrenergic receptor stimulation, and histamine through stimulation of H 2 receptors. As with endothelial cells, the changes in smooth muscle cell migration rate are also independent of changes in proliferation.
The platelet factors studied in the current study are present at varying concentrations in human platelets. The doses employed in this study are within the range of what would be expected at sites of vascular injury in vivo, assuming increased numbers of platelets at these sites, concentrations of serotonin, norepinephrine, histamine, TGF-/3, and 24 While the present study demonstrates the potency of each of the five factors, it would be expected that the influence of a particular factor on vascular cell migration in vivo would also be in part related to its relative concentration at the site of injury.
Although each of the five individual platelet factors decreased endothelial cell and increased smooth muscle cell migration, it is unlikely that these results are due to nonspecific effects of the treatments on the two cell types for the following reasons. First, the effects of serotonin, norepinephrine, and histamine were blocked by specific antagonists, in both the endothelial and smooth muscle cell studies. Second, the factors had different effects on cell proliferation but similar effects on migration since three of the agents decreased and two factors increased endothelial cell proliferation but all five decreased migration. Four factors increased and one factor did not change smooth muscle cell proliferation, yet all five factors increased smooth muscle migration. Third, other agents were studied that did not decrease endothelial cell or increase smooth muscle cell migration, since bFGF did not change endothelial cell migration and heparin decreased smooth muscle cell migration.
The model used to examine vascular cell migration in the present study is similar to models previously used for studying endothelial and smooth muscle cell migration in that migrating sheets of cells rather than individual cells are studied. 29 However, the model used in the present study examines radial sheet migration after loss of contact inhibition with removal of an encircling fence. This is in contrast to most other models for studying wound responses and migration in vitro that require mechanical debridement of a section of a confluent monolayer of cells. 13, 22, 25, 27 Such a procedure would be expected to remove varying amounts of underlying extracellular matrix and leave damaged cell components in the path of migration. The present studies were performed on a substrate of type I collagen since previous investigations from our laboratory have demonstrated that endothelial cell migration is maximal on a substrate of type I collagen 12 and that smooth muscle cell migration rate is not significantly different on a substrate of type I collagen as compared with laminin or type IV collagen (authors' unpublished data). Furthermore, while migration of endothelial cells in vivo following vessel wall injury occurs as a sheet of cells in two dimensions, migration of smooth muscle cells occurs as migrating clusters of cells in three dimensions within the media and then within two dimensions at the luminal surface.
-
30 Although the present system adequately models two-dimensional endothelial cell migration, it might be argued that three-dimensional smooth muscle cell migration is not as well modeled by a two-dimensional wound system. However, the present system does have significant advantages over mechanical debridement experiments as discussed above. Furthermore, the present model avoids significant disadvantages of the individual cell motility experiments . 34 The present study extends these observations by demonstrating the effect of individual platelet factors on endothelial cell sheet migration rather than on individual cell motility, the changes in proliferation rate of endothelial cells during migration, and the influence of changes in proliferation on changes in migration.
The observation in the present study that sustained TGF-/3 treatment is associated with a sustained decrease in endothelial cell sheet migration differs from previously reported results. 22 In a previous study, proliferation and migration of endothelial cells from a confluent culture into an area in which cells had been damaged and mechanically removed with a razor blade was reduced at 24 hours but not at 48 hours with 3.2 or 6.4 ng/ml TGF-/3. 22 It is possible that the absence of a sustained effect with TGF-/3 in the previous study may have been related to differences in the dose of TGF-0, the migration of cells on a plastic surface in the previous study rather than on a substrate of biomatrix, or the effect of cellular debris adherent to the plastic after mechanical debridement in the previous study. In addition, the present study demonstrates that it is unlikely that TGF-/J mediates a decrease in migration via a decrease in proliferation, as has been previously suggested, 22 since it is shown here that TGF-J3 mediates a similar decrease in migration of growth-arrested endothelial cells.
PDGF is associated with a decrease in endothelial cell migration. The data demonstrate that this effect is dose dependent, reversible, and independent of the associated decrease in proliferation. Previous investigators have also observed that PDGF is associated with a significant decrease in the proliferation rate of subconfluent cultures of human umbilical vein endothelial cells. 34 The data in the present study and the data from Wall et al 34 do not allow a determination whether the observed effects of PDGF on endothelial cells are receptor or nonreceptor mediated. Further, recent investigations have strongly suggested that there are at least two distinct PDGF receptors present on target cells and that the cell response is markedly influenced by both the population of PDGF receptors stimulated and the dimeric nature of the PDGF. 35 Although PDGF receptors have not been identified on endothelial cells with ligand binding studies, previous investigators have suggested that the absence of demonstrable ["'IJPDGF binding to endothelial cells may have been due to competition with an endogenously produced competitor. 36 The three amines, serotonin, histamine, and norepinephrine, act to decrease endothelial cell migration via activation of specific receptor systems. Although each of the amines is metabolized by endothelial cells and media to varying degrees, 37 it is apparent that the factors have sustained effects on endothelial cell migration at 6 days after replenishment of the factor at 3 days. Importantly, we observe that there are other sustained effects of the agent on cell function independent of the changes in migration since proliferation is also significantly changed after 2 days. It is likely that following initial stimulation, the factors induce marked changes in several aspects of cell function that are more long-standing, some of which may be responsible for the alterations in migration. Indeed, after 6 days, we have observed increases in cell size following serotonin treatment but decreases in cell size associated with norepinephrine or histamine treatment (authors' unpublished observations). In addition, the changes in cell size and migration may be related to changes in extracellular matrix production since the decrease in migration associated with TGF-/3 treatment is associated with an increase in both fibronectin messenger RNA and fibronectin synthesis. 38 While the present study identifies the kinetics of the changes in vascular cell migration associated with these platelet factors, the exact alterations in the cell machinery responsible for the changes in cell migration with each of these factors has not yet been identified.
Previous studies have observed an increase in the migration rate of smooth muscle cells treated with whole platelet lysates, 28 changes in individual cell motility or chemotaxis with individual platelet factors, 20 -21 and changes in the proliferation rate of subconfluent cultures treated with individual platelet factors. - 40 The present study extends these earlier studies by demonstrating the influence of individual platelet factors on smooth muscle cell migration, changes in the proliferation rate during migration, and the influence of changes in proliferation on changes in smooth muscle cell migration.
The small changes in migration rate observed in the present study with mitomycin are similar to observations in previous studies in which the influence of growth-airesting treatment on migration was examined for periods usually briefer than the 6-day period used in the present study. 13.14,25,26,29 j n addition, the present study uses growth-arresting treatment to demonstrate that the influence of individual platelet factors on both endothelial and smooth muscle cell migration kinetics are independent of changes in proliferation.
The present results suggest that a portion of the clinically beneficial effects of antiplatelet therapy may be due to a reduction in the detrimental effects of platelet factors on endothelial and smooth muscle cell migration at sites of vascular injury in patients. Hence, it is possible that enhanced endothelial cell and reduced smooth muscle cell migration expected with antiplatelet therapy might contribute to the mechanisms underlying the clinical benefits of this therapy. 6 It might then be expected that these beneficial effects on the blood vessel wall response to injury might contribute to the observed improvements in patients treated with antiplatelet therapy for such conditions as unstable angina, threatened stroke, and peripheral vascular disease and following myocardial infarction, percutaneous transluminal coronary angioplasty, and placement of peripheral or coronary artery bypass grafts. 41 -46 In summary, the present study demonstrates that individual soluble platelet factors act to inhibit endothelial cell migration and to augment smooth muscle cell migration in an in vitro wound assay. These changes in migration kinetics are independent of associated changes in proliferation and occur via activation of specific membrane receptors. It would be expected that the actions of these platelet factors would contribute to worsened vascular injury in vivo by reducing endothelial cell closure of the wounded vessel wall and by enhancing smooth muscle cell migration into the intima. Indeed, both an increase in endothelial cell migration to close the wounded vessel and a reduction in pathological smooth muscle cell migration into the intima associated with antiplatelet therapy might contribute in part to the beneficial effect of this therapy in patients with diverse cardiovascular diseases.
